BIOTRONIK Orsiro Pre-Marketing Registration

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.

Also called NCT02870985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 440 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02870985
Other papers using this trial's data
  • Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial Clinical therapeutics, 2020-04 DOI, PubMed 32268942

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02870985. Randomized; single masking; primary purpose treatment. Start 2015-07-14 (actual); primary completion 2017-04-06 (actual). Results posted on 2024-03-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BIOTRONIK Orsiro Pre-Marketing Registration
Acronym
BIOFLOW-VI
Intervention (Device)
Coronary Stent
Lead sponsor
Biotronik (Beijing) Medical Device Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02870985
Content hash
3198df180c78183772a08adf8f992c6a0e4162e419ad4df09f62adbbf6cf96b1